AND017

Kind Pharmaceuticals' AND017, an oral small molecule, has been granted orphan drug status by the FDA for the treatment of sickle cell disease (SCD).

AND017 demonstrates favorable pharmacokinetics and safety in Phase I trials, with half-life ranging from 10.1 to 19.7 hours.

AND017 demonstrated favorable pharmacokinetics and safety in a Phase 1 trial with healthy subjects, showing preliminary effects on EPO and Hb levels.

The FDA has granted Orphan Drug Designation to AND017, a novel hemoglobin-elevating agent developed by Kind Pharmaceutical, for the treatment of sickle cell disease (SCD).

The FDA has granted Orphan Drug Designation to AND017, a drug developed by Kind Pharmaceutical, for the treatment of Sickle Cell Disease (SCD).